Nalaganje...
BRAF-directed Therapy in Metastatic Colorectal Cancer
Activating BRAF mutations occur in approximately 5–10% of metastatic colorectal cancer (mCRC) patients, mostly V600E mutation, and it is associated with distinct clinical and pathological features. To date, there are no approved treatments to target this mutation. BRAF inhibitor monotherapy has limi...
Shranjeno v:
| izdano v: | Cancer J |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2016
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4922502/ https://ncbi.nlm.nih.gov/pubmed/27341594 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PPO.0000000000000189 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|